|
Studienakronym |
Krankheitsentität  |
Vollständiger Titel / Beschreibung |
Status |
|
|
AIO-STO-0217 - INTEGA |
Ösophagus, nicht näher bezeichnet
[C15.9]
|
Ipilimumab in Kombination mit Nivolumab und Trastuzumab bei bisher unbehandelten HER2 positiven Patienten mit lokal fortgeschrittenem oder metastasiertem EsophagoGastric Adenokarzinom
Die randomisierte Phase 2 INTEGA Studie.
|
 |
 |
|
|
AIO-STO-0417 (Moonlight) |
Magen, nicht näher bezeichnet
[C16.9]
|
Modified FOLFOX plus/minus Nivolumab and Ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction –
A randomized phase 2 Trial
|
|
|
|
|
AIO-YMO-0111 (MATEO) |
Ösophagus, nicht näher bezeichnet
[C15.9]
|
Randomized controlled trial of S-1 maintenance therapy in metastatic esophagogastric carcinoma MATEO (maintenance Teysuno in esophagogastric carcinoma)
|
 |
|
|
|
AKRENDO |
Endometriose, nicht näher bezeichnet
[N80.9]
|
A randomized, placebo-controlled, double-blind, parallel-group, multi-center,
exploratory dose-response study to assess the efficacy and safety of different oral doses
of BAY 1128688 in women with symptomatic endometriosis over a 12-week Treatment period
Exploratory dose-response study in endometriosis patients
|
|
|
|
|
Akute HCV IV Studie |
Chronische aktive Hepatitis, anderenorts nicht klassifiziert
[K73.2]
|
Behandlung mit Sofosbuvir/Ledipasvir kombination bei Akute Hepatitis C Virus Infektion-Genotyp 1 Interferon freie Studie.
|
|
|
|
ALL Register |
Akute lymphatische Leukämie [ALL]
[C91.0-]
|
GMALL-Register und Biomaterialbank
Biomaterialsammlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen
|
|
|
|
|
ALL SCT ped 2012 FORUM |
Transplantation von hämatopoetischen Stammzellen aus dem Knochenmark
[-]
|
Allogeneic Stem Cell Transplantation in Children and Adolescents with Acute Lymphoblastic Leukaemia
|
|
|
|
|
ALPACA |
Bösartige Neubildung des Pankreas
[C25.-]
|
Induction treatment with nab-paclitaxel/gemcitabine for first-line treatment of metastatic pancreatic cancer followed by either alternating application of gemcitabine monotherapy and nab-paclitaxel/gemcitabine or continuing application of nab-paclitaxel/gemcitabine: A randomized phase II study
|
|
|
|
|
Alpha-RT |
Bösartige Neubildung der Prostata
[C61]
|
Phase II open-label study to evaluate the efficacy and safety of Radium-223 dichloride in combination with external beam radiotherapy (EBRT) vs. external beam radiotherapy alone in the treatment of advanced castration resistant prostate carcinoma with limited bone metastases
|
 |
|
|
|
Alpharadin BAY 88-8223 |
Bösartige Neubildung der Prostata
[C61]
|
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
|
|
|
|
|
ALPS |
Ductus pancreaticus
[C25.3]
|
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Different Combinations in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
|
|
|
|
|
ALTERNATIVE |
Follikuläres Lymphom, nicht näher bezeichnet
[C82.9]
Follikuläres Lymphom Grad I
[C82.0]
Follikuläres Lymphom Grad II
[C82.1]
Follikuläres Lymphom Grad III, nicht näher bezeichnet
[C82.2]
|
A prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib) in Combination with Obinutuzumab (GA 101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
|
|
|
|
|
Alternative |
Follikuläres Lymphom Grad I
[C82.0]
|
A prospective multicenter Phase 2 Study of the Chemotherapy-free Comination of the Bruton´s Tyrosine Kinase Inhibitor,PCI-32765(Ibrutinib) in Combination with Obinutuzumab (GA101) in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden
|
|
|
|
|
ALTTO ( GSK ) |
Mammakarzinom
[C50.9]
|
Adjuvant Pivotal Trial of Herceptin or Lapatinib or Dual Inhibition of ErB2
|
|
|
|
|
AMBER |
Nicht näher bezeichnete HIV-Krankheit [Humane Immundefizienz-Viruskrankheit]
[B24]
|
Eine randomisierte, aktiv kontrollierte, doppelblinde klinische Prüfung der Phase-3 zur Evaluation der Wirksamkeit und Sicherheit einer einmal täglich eingenommenen Fixdosis-Kombinationstablette Darunavir / Cobiscistat / Emtricitabin / Tenofoviralafenamid (D/C/F/TAF) im Vergleich mit einer einmal täglich eingenommenen Kombinationstherapie bestehend aus einer Fixdosis-Kombinationstablette Darunavir / Cobicistat und einer fest Fixdosis-Kombinationstablette Emtricitabin / Tenofovirdisoproxilfumarat zur Behandlung von nicht antiretroviral vorbehandelten Patienten mit HIV-1-Infektion (Humanes Immundefizienz-Virus Typ 1)
|
|
|
|
|
AMBIGUARD |
Infektiologie
[-]
Lymphatische Leukämie
[C91.-]
|
GS-EU-131-0247 A Phase 3, Double-Blind, Multicenter, Randomized,Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL)
|
|
|
|
|
AMG 211 |
Solide Tumore
[-]
|
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 211 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Gastrointestinal Adenocarcinoma
|
|
|
|
|
AMG 330 |
Akute myeloblastische Leukämie [AML]
[C92.0-]
|
A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
|
 |
|
|
|
AMG 562 20170533 |
|
A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability,
Pharmacokinetics, and Efficacy of AMG 562 in Subjects With Relapsed / Refractory Diffuse
Large B Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
|
|
|
|
|
AMG655 |
Bösartige Neubildung am Rektosigmoid, Übergang
[C19]
|
A Phase 1b/2 Trial of AMG 655 in Combination with Panitumumab in Subjects with Metastatic Colorectal Cancer
|
|
|
|
|
AML Register |
Akute myeloblastische Leukämie [AML]
[C92.0-]
|
AML-Register und Biomaterialdatenbank der Studienallianz Leukämie(SAL)und der AML Cooperative Group(AML-CG)
|
|
|
|
|
AML-BFM 2012 |
Akute myeloblastische Leukämie [AML]
[C92.0]
|
Klinische Prüfung zur Behandlung der akuten myeloischen Leukämien bei Kindern und Jugendlichen
|
|
|
|
|
AML-Blast |
Akute myeloblastische Leukämie [AML]
[C92.0]
|
A double-blind, placebo-controlled, randomized, multicenter, Phase II study to assess efficacy of BL-8040 Addition to conSolidation Therapy in AML patients
|
|
|
|
|
AML-CG 2008 Version 1.0 |
Akute myeloblastische Leukämie [AML]
[C92.0-]
|
A Randomized phase III trial for Primary Induction Therapy in AML Comparing a Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside (AraC) and mitoxantrone) and Standard Double Induction with Allogeneic Stem Cell Transplantation as Preferred Consolidation Therapy
|
|
|
|
|
AMLSG 09-09 |
Akute myeloblastische Leukämie [AML]
[C92.0]
|
Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation Versand mit GO, T: 07345-800610 Info Ulm, Follow Up bis September 2021
|
|
|
